Drug consumption and melanocytic nevi: correlation between oral contraceptives or hormone replacement therapy and a high melanocytic nevi count.


Journal

European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
ISSN: 1473-5709
Titre abrégé: Eur J Cancer Prev
Pays: England
ID NLM: 9300837

Informations de publication

Date de publication:
07 2020
Historique:
pubmed: 1 10 2019
medline: 10 7 2021
entrez: 1 10 2019
Statut: ppublish

Résumé

The prolonged use of drugs such as beta-blockers, acetylsalicylic acid, omeprazole, statins, oral contraceptives and hormone replacement therapy might have some role in melanocytic nevi development and be ultimately linked to melanoma risk. Aims of the study were to evaluate a possible association between the above-mentioned drugs and features such as number and atypia of melanocytic nevi in long-term users. We retrospectively looked at pharmacological, clinical and dermoscopic records of 1321 patients that attended our unit for routine mole check between January 2013 and January 2018. Patients were divided into two groups (low or high melanocytic nevi count), and multivariate analysis was performed with regards to the presence and number of melanocytic nevi and drug assumption. A positive association between the use of oral contraceptives or hormone replacement therapy (P = 0.012) and a high melanocytic nevi count was found through multivariate analysis, after adjusting for sex, age and multiple confounding factors, such as freckles, phototype and a reported history of sun exposure and sunburns. Further prospective studies are necessary to establish whether women using oral contraceptives or on hormone replacement therapy should undergo periodic monitoring of pigmented lesions.

Identifiants

pubmed: 31567537
doi: 10.1097/CEJ.0000000000000545
pii: 00008469-202007000-00009
doi:

Substances chimiques

Contraceptives, Oral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

338-341

Références

Borges V, Puig S, Malvehy J. Melanocytic nevi, melanoma, and pregnancy[in Spanish]. Actas Dermosifiliogr. 2011; 102:650–657
De Giorgi V, Gandini S, Grazzini M, Benemei S, Marchionni N, Geppetti P. Effect of β-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death. Mayo Clin Proc. 2013; 88:1196–1203
Echeverria BJ, Bulliard L, Guill C, Nagore E. Indicators for the total number of melanocytic naevi: an adjunct for screening campaigns. Observational study on 292 patients. Br J Dermatol. 2014; 70:144–149
Gamba CA, Swetter SM, Stefanick ML, Kubo J, Desai M, Spaunhurst KM, et al. Aspirin is associated with lower melanoma risk among postmenopausal caucasian women: the women’s health initiative. Cancer. 2013; 119:1562–1569
Gandini S, Iodice S, Koomen E, Di Pietro A, Sera F, Caini S. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. Eur J Cancer. 2011; 47:2607–2617
Jee SH, Lee SY, Chiu HC, Chang CC, Chen T. Effects of estrogen and estrogen receptor in normal human melanocytes. Biochem Biophys Res Commun. 1994; 199:1407–1412
Marino ML, Fais S, Djavaheri-Mergny M, Villa A, Meschini S, Lozupone F, et al. Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death Dis. 2010; 1:e87
Ohata C, Tadokoro T, Itami S. Expression of estrogen receptor beta in normal skin, melanocytic nevi and malignant melanomas. J Dermatol. 2008; 35:215–221
Pich C, Teiti I, Rochaix P, Mariamé B, Couderc B, Favre G, Tilkin-Mariamé A. Statins reduce melanoma development and metastasis through MICA overexpression. Front Immunol. 2013; 4:62
Wiedemann C, Nägele U, Schramm G, Berking C. Inhibitory effects of progestogens on the estrogen stimulation of melanocytes in vitro. Contraception. 2009; 80:292–298

Auteurs

Roberta Colucci (R)

Section of Dermatology, Department of Health Sciences, University of Florence, Ospedale Piero Palagi.

Carlotta Buzzoni (C)

Tuscany Cancer Registry, Clinical Epidemiology Unit, Oncological Network, Prevention and Research Institute ISPRO, Florence, Italy.

Federica Dragoni (F)

Section of Dermatology, Department of Health Sciences, University of Florence, Ospedale Piero Palagi.

Alessandro Traniello Gradassi (A)

Department of Dermatology and Venereal Diseases, St. Orsola-Malpighi Hospital, Bologna, Italy; Portions of this research were done at affiliation ().

Massimiliano Galeone (M)

Section of Dermatology, Department of Health Sciences, University of Florence, Ospedale Piero Palagi.

Emanuele Crocetti (E)

Romagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), Italy.

Silvia Moretti (S)

Section of Dermatology, Department of Health Sciences, University of Florence, Ospedale Piero Palagi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH